{'52WeekChange': 0.4649061,
 'SandP52WeekChange': None,
 'address1': '12780 El Camino Real',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 125.25,
 'askSize': 3100,
 'averageDailyVolume10Day': 611962,
 'averageVolume': 861255,
 'averageVolume10days': 611962,
 'beta': 1.341176,
 'beta3Year': None,
 'bid': 124.51,
 'bidSize': 1000,
 'bookValue': 7.546,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 127.19,
 'dayLow': 124.27,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 40.395,
 'enterpriseToRevenue': 12.814,
 'enterpriseValue': 11363513344,
 'exDividendDate': 820195200,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 125.52286,
 'fiftyTwoWeekHigh': 136.26,
 'fiftyTwoWeekLow': 72.14,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 91650445,
 'forwardEps': 5.08,
 'forwardPE': 24.64567,
 'fromCurrency': None,
 'fullTimeEmployees': 750,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.01043,
 'heldPercentInstitutions': 0.99052,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/neurocrine.com',
 'longBusinessSummary': 'Neurocrine Biosciences, Inc., a commercial-stage '
                        'biopharmaceutical company, discovers and develops '
                        'therapeutics for the treatment of neurological, '
                        'endocrine, and psychiatric disorders in the United '
                        'States. The company offers INGREZZA (valbenazine), a '
                        'vesicular monoamine transporter 2 inhibitor (VMAT2) '
                        'for the treatment of tardive dyskinesia; and '
                        'ORILISSA, a gonadotropin-releasing hormone antagonist '
                        'for use in the treatment of endometriosis. Its '
                        'product candidates in clinical development include '
                        'elagolix that has completed Phase III clinical trial '
                        'for uterine fibroids; opicapone, a '
                        'catechol-O-methyltransferase inhibitor used as an '
                        'adjunct therapy to levodopa/DOPA decarboxylase '
                        "inhibitors for adult patients with Parkinson's "
                        'disease; and NBI-74788, which is in Phase III '
                        'clinical trial for the treatment of congenital '
                        "adrenal hyperplasia. The company's products under "
                        'development include NBIb-1817, an AADC gene '
                        'replacement therapy, which is in Phase II clinical '
                        "trial for the treatment of Parkinson's disease; "
                        'NBI-921352, a Nav1.6 sodium channel inhibitor for the '
                        'treatment of pediatric patients with SCN8A-DEE, as '
                        'well as other indications, such as adult focal '
                        'epilepsy; ACT-709478, an orally active and brain '
                        'penetrating T-type calcium channel blocker for use in '
                        'certain forms of generalized epilepsy; and VMAT2 '
                        'inhibitor for the treatment of various neurology '
                        'and/or psychiatry disorders. Neurocrine Biosciences, '
                        'Inc. has collaborations and agreements with AbbVie '
                        'Inc.; BIAL Â\x96 Portela & Ca, S.A.; Voyager '
                        'Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; '
                        'Mitsubishi Tanabe Pharma Corporation; Idorsia '
                        'Pharmaceuticals Ltd; and Takeda Pharmaceutical '
                        'Company Limited. The company was founded in 1992 and '
                        'is headquartered in San Diego, California.',
 'longName': 'Neurocrine Biosciences, Inc.',
 'market': 'us_market',
 'marketCap': 11626711040,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_32073',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 176512000,
 'nextFiscalYearEnd': 1640908800,
 'open': 127.03,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.28,
 'phone': '858-617-7600',
 'previousClose': 128.15,
 'priceHint': 2,
 'priceToBook': 16.591572,
 'priceToSalesTrailing12Months': 13.1110525,
 'profitMargins': 0.19905001,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 127.19,
 'regularMarketDayLow': 124.27,
 'regularMarketOpen': 127.03,
 'regularMarketPreviousClose': 128.15,
 'regularMarketPrice': 127.03,
 'regularMarketVolume': 478291,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 92865104,
 'sharesPercentSharesOut': 0.0519,
 'sharesShort': 4824040,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4723564,
 'shortName': 'Neurocrine Biosciences, Inc.',
 'shortPercentOfFloat': 0.052600004,
 'shortRatio': 5.25,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'NBIX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 1.823,
 'trailingPE': 68.678,
 'twoHundredDayAverage': 107.227196,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '2532fb18-868f-3936-991c-d8060c56d55f',
 'volume': 478291,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.neurocrine.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92130'}